IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-57263-1.html
   My bibliography  Save this article

Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial

Author

Listed:
  • Andrew J. Brenner

    (Mays Cancer Center at UT Health San Antonio)

  • Toral Patel

    (UT Southwestern Medical Center of Dallas)

  • Ande Bao

    (Case Western Reserve University)

  • William T. Phillips

    (Mays Cancer Center at UT Health San Antonio)

  • Joel E. Michalek

    (Mays Cancer Center at UT Health San Antonio)

  • Michael Youssef

    (UT Southwestern Medical Center of Dallas)

  • Jeffrey S. Weinberg

    (University of Texas MD Anderson Cancer Center)

  • Carlos Kamiya Matsuoka

    (University of Texas MD Anderson Cancer Center)

  • Marc H. Hedrick

    (Plus Therapeutics)

  • Norman LaFrance

    (Plus Therapeutics)

  • Melissa Moore

    (Plus Therapeutics)

  • John R. Floyd

    (Mays Cancer Center at UT Health San Antonio)

Abstract

Rhenium (186Re) Obisbemeda (186RNL), chelated-186Re encapsulated in nanoliposomes and delivered to brain tumors via convection enhanced delivery (CED), was evaluated in a Phase 1 dose escalation trial (NCT01906385). The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included safety and tolerability, dose distribution, the overall response rate (ORR), disease-specific progression-free survival (PFS), and overall survival (OS). 21 patients received up to 22.3 mCi 186RNL over 6 dosing cohorts. Most adverse events (AEs) were unrelated to 186RNL and the MTD was not reached. Although not predefined outcomes, the mOS and mPFS were 11 and 4 months, respectively, and found to correlate with radiation absorbed dose to the tumor and percent tumor treated. When dichotomized by absorbed dose of 100 Gy, the mOS and mPFS were 17 months and 6 months, respectively, for >100 Gy, compared to 6 (mOS) and 2 (mPFS) months, respectively, for

Suggested Citation

  • Andrew J. Brenner & Toral Patel & Ande Bao & William T. Phillips & Joel E. Michalek & Michael Youssef & Jeffrey S. Weinberg & Carlos Kamiya Matsuoka & Marc H. Hedrick & Norman LaFrance & Melissa Moore, 2025. "Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial," Nature Communications, Nature, vol. 16(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57263-1
    DOI: 10.1038/s41467-025-57263-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-57263-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-57263-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57263-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.